<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00999544</url>
  </required_header>
  <id_info>
    <org_study_id>09-0446</org_study_id>
    <secondary_id>R01DA027031</secondary_id>
    <nct_id>NCT00999544</nct_id>
  </id_info>
  <brief_title>Aprepitant Effects on Oxycodone Response</brief_title>
  <official_title>New Neural Drug Targets: An Evaluation of the Effects of Aprepitant on the Response to Oxycodone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sharon Walsh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Kentucky</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Addressing the issue of opioid dependence and tolerance has public health implications for
      the treatment of opioid abuse (both heroin as well as pharmaceutical opioids) and for the
      treatment of pain. Recent preclinical data suggest a role for Substance P (NK-1) receptors in
      modulating both the acute and chronic response to opioids. The objective of this study is to
      determine whether pretreatment with aprepitant, a selective neurokinin-1 (NK-1) antagonist
      can reduce the direct response to an opioid agonist (oxycodone) on measures related to abuse
      liability and reinforcing effects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Healthy adult volunteers with histories of illicit opioid use by the intranasal and oral
      routes will be admitted to this 6-week inpatient, crossover study. They will participate in
      15 experimental test sessions, each lasting approximately 6.5 hours, during which they will
      receive a range of acute doses of aprepitant, including placebo, followed by challenge with
      oxycodone or placebo (given intranasally or orally). Multi-dimensional outcomes, including
      physiological (blood pressure, oxygen saturation, pupil diameter), subjective (questionnaires
      related to mood, abuse liability) and observer ratings will be collected repeatedly
      throughout each session. Data will be analyzed using parametric approaches to within-subject
      designs.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">April 2011</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Within subject crossover designed that examined 15 experimental conditions within a single group of participants</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Abuse Liability Proxy</measure>
    <time_frame>42 days</time_frame>
    <description>Visual analog scale ratings (from 0-100) on the subject-rated measure of &quot;How much do you like the drug?&quot; with higher scores indicating greater abuse liability (and 100 anchored with &quot;extremely&quot; and zero indicating none anchored with &quot;none at all.&quot; Data were collected across multiple time points but the peak maximum score was used for the primary outcome measure.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Respiration Depression</measure>
    <time_frame>42 days</time_frame>
    <description>Respiration rate measured over 60 seconds. Data were collected across multiple time points, but the peak minimum score was used for this outcome measure.</description>
  </secondary_outcome>
  <number_of_arms>15</number_of_arms>
  <enrollment type="Actual">9</enrollment>
  <condition>Narcotic Abuse</condition>
  <arm_group>
    <arm_group_label>Placebo aprepitant/0 mg oxycodone IN PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo aprepitant/Placebo oxycodone IN/PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo aprepitant/ oxycodone 15 IN 0 PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo aprepitant/ oxycodone 15 IN 0 PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo aprepitant/ oxycodone 30 IN 0 PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo aprepitant/ oxycodone 30 IN 0 PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo aprepitant/ oxycodone 0 IN 20 PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo aprepitant/ oxycodone 0 IN 20 PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo aprepitant/ oxycodone 0 IN 40 PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo aprepitant/ oxycodone 0 IN 40 PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 0 IN 0 PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aprepitant 40 mg/ oxycodone 0 IN 0 PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 0 IN 20 PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aprepitant 40 mg/ oxycodone 0 IN 20 PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 0 IN 40 PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aprepitant 40 mg/ oxycodone 0 IN 40 PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 15 IN 0 PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aprepitant 40 mg/ oxycodone 15 IN 0 PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 30 IN 0 PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aprepitant 40 mg/ oxycodone 30 IN 0 PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 0 IN 0 PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aprepitant 200 mg/ oxycodone 0 IN 0 PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 0 IN 20 PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aprepitant 200 mg/ oxycodone 0 IN 20 PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 0 IN 40 PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aprepitant 200 mg/ oxycodone 0 IN 40 PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 15 IN 0 PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aprepitant 200 mg/ oxycodone 15 IN 0 PO</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 30 IN 0 PO</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Aprepitant 200 mg/ oxycodone 30 IN 0 PO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant 0mg</intervention_name>
    <description>Aprepitant 0mg, p.o. pretreatment</description>
    <arm_group_label>Placebo aprepitant/0 mg oxycodone IN PO</arm_group_label>
    <arm_group_label>Placebo aprepitant/ oxycodone 15 IN 0 PO</arm_group_label>
    <arm_group_label>Placebo aprepitant/ oxycodone 30 IN 0 PO</arm_group_label>
    <arm_group_label>Placebo aprepitant/ oxycodone 0 IN 20 PO</arm_group_label>
    <arm_group_label>Placebo aprepitant/ oxycodone 0 IN 40 PO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant 40mg</intervention_name>
    <description>Aprepitant 40mg, p.o. pretreatment</description>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 0 IN 0 PO</arm_group_label>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 0 IN 20 PO</arm_group_label>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 0 IN 40 PO</arm_group_label>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 15 IN 0 PO</arm_group_label>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 30 IN 0 PO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aprepitant 200mg</intervention_name>
    <description>Aprepitant 200mg, p.o. pretreatment</description>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 0 IN 0 PO</arm_group_label>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 0 IN 20 PO</arm_group_label>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 0 IN 40 PO</arm_group_label>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 15 IN 0 PO</arm_group_label>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 30 IN 0 PO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone 0mg, p.o.</intervention_name>
    <description>Oxycodone 0mg, p.o.</description>
    <arm_group_label>Placebo aprepitant/0 mg oxycodone IN PO</arm_group_label>
    <arm_group_label>Placebo aprepitant/ oxycodone 15 IN 0 PO</arm_group_label>
    <arm_group_label>Placebo aprepitant/ oxycodone 30 IN 0 PO</arm_group_label>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 0 IN 0 PO</arm_group_label>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 15 IN 0 PO</arm_group_label>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 30 IN 0 PO</arm_group_label>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 0 IN 0 PO</arm_group_label>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 15 IN 0 PO</arm_group_label>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 30 IN 0 PO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone 20mg, p.o.</intervention_name>
    <description>Oxycodone 20mg, p.o.</description>
    <arm_group_label>Placebo aprepitant/ oxycodone 0 IN 20 PO</arm_group_label>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 0 IN 20 PO</arm_group_label>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 0 IN 20 PO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone 40mg, p.o.</intervention_name>
    <description>Oxycodone 40mg, p.o.</description>
    <arm_group_label>Placebo aprepitant/ oxycodone 0 IN 40 PO</arm_group_label>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 0 IN 40 PO</arm_group_label>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 0 IN 40 PO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone 0mg, IN</intervention_name>
    <description>Oxycodone 0mg, IN</description>
    <arm_group_label>Placebo aprepitant/0 mg oxycodone IN PO</arm_group_label>
    <arm_group_label>Placebo aprepitant/ oxycodone 0 IN 20 PO</arm_group_label>
    <arm_group_label>Placebo aprepitant/ oxycodone 0 IN 40 PO</arm_group_label>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 0 IN 0 PO</arm_group_label>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 0 IN 20 PO</arm_group_label>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 0 IN 40 PO</arm_group_label>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 0 IN 0 PO</arm_group_label>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 0 IN 20 PO</arm_group_label>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 0 IN 40 PO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone 15mg, IN</intervention_name>
    <description>Oxycodone 15mg, IN</description>
    <arm_group_label>Placebo aprepitant/ oxycodone 15 IN 0 PO</arm_group_label>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 15 IN 0 PO</arm_group_label>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 15 IN 0 PO</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxycodone 30mg, IN</intervention_name>
    <description>Oxycodone 30mg, IN</description>
    <arm_group_label>Placebo aprepitant/ oxycodone 30 IN 0 PO</arm_group_label>
    <arm_group_label>Aprepitant 40 mg/ oxycodone 30 IN 0 PO</arm_group_label>
    <arm_group_label>Aprepitant 200 mg/ oxycodone 30 IN 0 PO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Recreational user of opioids

          -  Healthy

          -  Ages 18-55 years old

          -  Able to provide informed consent

        Exclusion Criteria:

          -  Ongoing medical or psychiatric condition that would be contraindicated for
             participation

          -  Past 30 day use of and P4503A4 inhibitor
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharon L Walsh, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Kentucky</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Walsh SL, Heilig M, Nuzzo PA, Henderson P, Lofwall MR. Effects of the NK1 antagonist, aprepitant, on response to oral and intranasal oxycodone in prescription opioid abusers. Addict Biol. 2013 Mar;18(2):332-43. doi: 10.1111/j.1369-1600.2011.00419.x. Epub 2012 Jan 19.</citation>
    <PMID>22260216</PMID>
  </results_reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 20, 2009</study_first_submitted>
  <study_first_submitted_qc>October 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 21, 2009</study_first_posted>
  <results_first_submitted>November 13, 2012</results_first_submitted>
  <results_first_submitted_qc>July 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 23, 2013</results_first_posted>
  <last_update_submitted>August 3, 2017</last_update_submitted>
  <last_update_submitted_qc>August 3, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Kentucky</investigator_affiliation>
    <investigator_full_name>Sharon Walsh</investigator_full_name>
    <investigator_title>Director Center on Drug and Alcohol Research</investigator_title>
  </responsible_party>
  <keyword>opioid</keyword>
  <keyword>oxycodone</keyword>
  <keyword>NK1 antagonist</keyword>
  <keyword>aprepitant</keyword>
  <keyword>intranasal</keyword>
  <keyword>abuse</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxycodone</mesh_term>
    <mesh_term>Aprepitant</mesh_term>
    <mesh_term>Fosaprepitant</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>All recruitment was conducted through a research clinic at a public university.</recruitment_details>
      <pre_assignment_details>Subjects were initially screened for inclusion/exclusion criteria. Fifteen subjects signed the screening consent but only nine were qualified to participate and signed the study consent. One subject left the study before receiving any interventions.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Within-subject Crossover Design</title>
          <description>All subjects received exposure to every study condition in random order. During each of 15 separate test sessions, subjects received pretreatment with aprepitant (0, 40 or 200 mg) followed by a single challenge with a oxycodone (15 or 30, intranasal; 20 or 40 mg) or placebo. The fifteen dose conditions were administered in random order and each subject was exposed to each dose combination once.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Crossover Within Subject</title>
          <description>All subjects were exposed to every condition.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.3" spread="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Abuse Liability Proxy</title>
        <description>Visual analog scale ratings (from 0-100) on the subject-rated measure of &quot;How much do you like the drug?&quot; with higher scores indicating greater abuse liability (and 100 anchored with &quot;extremely&quot; and zero indicating none anchored with &quot;none at all.&quot; Data were collected across multiple time points but the peak maximum score was used for the primary outcome measure.</description>
        <time_frame>42 days</time_frame>
        <population>Prior laboratory-based within subject studies of the pharmacodynamic response to opioid challenges. The within subject data analysis does not lend itself to reporting data in the format provided below.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo-Placebo (in and po)</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O2">
            <title>Aprepitant 40 mg - Placebo</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O3">
            <title>Aprepitant 200 mg- Placebo</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O4">
            <title>Placebo- 15 mg Oxycodone Intranasal</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O5">
            <title>Placebo- 30 mg Oxycodone Intranasal</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O6">
            <title>Placebo- 20 mg Oxycodone Oral</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O7">
            <title>Placebo - 40 mg Oxycodone Oral</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O8">
            <title>Aprepitant 40 mg- 15 mg Oxycodone Intranasal</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O9">
            <title>Aprepitant 40 mg - 30 mg Oxycodone Intranasal</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O10">
            <title>Aprepitant 40 mg- 20 mg Oxycodone Oral</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O11">
            <title>Aprepitant 40 mg - 40 mg Oxycodone Oral</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O12">
            <title>Aprepitant 200 mg - 15 mg Oxycodone Intranasal</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O13">
            <title>Aprepitant 200 mg - 30 mg Oxycodone Intranasal</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O14">
            <title>Aprepitant 200 mg- 20 Oxycodone Oral</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
          <group group_id="O15">
            <title>Aprepitant 200 mg- 40 Oxycodone Oral</title>
            <description>All subjects received exposure to this study condition once.</description>
          </group>
        </group_list>
        <measure>
          <title>Abuse Liability Proxy</title>
          <description>Visual analog scale ratings (from 0-100) on the subject-rated measure of &quot;How much do you like the drug?&quot; with higher scores indicating greater abuse liability (and 100 anchored with &quot;extremely&quot; and zero indicating none anchored with &quot;none at all.&quot; Data were collected across multiple time points but the peak maximum score was used for the primary outcome measure.</description>
          <population>Prior laboratory-based within subject studies of the pharmacodynamic response to opioid challenges. The within subject data analysis does not lend itself to reporting data in the format provided below.</population>
          <units>units on a scale (points 0-100)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="8"/>
                <count group_id="O12" value="8"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="8"/>
                <count group_id="O15" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.197" spread="0.197"/>
                    <measurement group_id="O2" value="0.483" spread="0.397"/>
                    <measurement group_id="O3" value="0.159" spread="0.159"/>
                    <measurement group_id="O4" value="7.678" spread="2.656"/>
                    <measurement group_id="O5" value="17.450" spread="4.275"/>
                    <measurement group_id="O6" value="9.850" spread="5.090"/>
                    <measurement group_id="O7" value="16.646" spread="4.203"/>
                    <measurement group_id="O8" value="8.543" spread="2.892"/>
                    <measurement group_id="O9" value="15.092" spread="4.706"/>
                    <measurement group_id="O10" value="13.281" spread="4.009"/>
                    <measurement group_id="O11" value="17.244" spread="4.788"/>
                    <measurement group_id="O12" value="17.195" spread="4.897"/>
                    <measurement group_id="O13" value="28.211" spread="4.365"/>
                    <measurement group_id="O14" value="8.196" spread="2.667"/>
                    <measurement group_id="O15" value="26.322" spread="3.702"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
              <group_id>O6</group_id>
              <group_id>O7</group_id>
              <group_id>O8</group_id>
              <group_id>O9</group_id>
              <group_id>O10</group_id>
              <group_id>O11</group_id>
              <group_id>O12</group_id>
              <group_id>O13</group_id>
              <group_id>O14</group_id>
              <group_id>O15</group_id>
            </group_id_list>
            <groups_desc>Area-under-the-curve (AUC) scores were derived from time course data and analyzed using two-factor ANOVA [aprepitant dose (3 levels)x oxycodone dose (3 levels)].
All analyses were conducted using SAS 9.1 for Windows (SAS Institute Inc., Cary, NC, USA) and were considered significant when P 0.05.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;.05</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Respiration Depression</title>
        <description>Respiration rate measured over 60 seconds. Data were collected across multiple time points, but the peak minimum score was used for this outcome measure.</description>
        <time_frame>42 days</time_frame>
        <population>Prior laboratory-based within subject studies of the pharmacodynamic response to opioid challenges.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Aprepitant/0 mg Oxycodone IN PO</title>
            <description>Placebo aprepitant/Placebo oxycodone IN/PO
Aprepitant 0mg: Aprepitant 0mg, p.o. pretreatment
Oxycodone 0mg, p.o.: Oxycodone 0mg, p.o.
Oxycodone 0mg, IN: Oxycodone 0mg, IN</description>
          </group>
          <group group_id="O2">
            <title>Placebo Aprepitant/ Oxycodone 15 IN 0 PO</title>
            <description>Placebo aprepitant/ oxycodone 15 IN 0 PO
Aprepitant 0mg: Aprepitant 0mg, p.o. pretreatment
Oxycodone 0mg, p.o.: Oxycodone 0mg, p.o.
Oxycodone 15mg, IN: Oxycodone 15mg, IN</description>
          </group>
          <group group_id="O3">
            <title>Placebo Aprepitant/ Oxycodone 30 IN 0 PO</title>
            <description>Placebo aprepitant/ oxycodone 30 IN 0 PO
Aprepitant 0mg: Aprepitant 0mg, p.o. pretreatment
Oxycodone 0mg, p.o.: Oxycodone 0mg, p.o.
Oxycodone 30mg, IN: Oxycodone 30mg, IN</description>
          </group>
          <group group_id="O4">
            <title>Placebo Aprepitant/ Oxycodone 0 IN 20 PO</title>
            <description>Placebo aprepitant/ oxycodone 0 IN 20 PO
Aprepitant 0mg: Aprepitant 0mg, p.o. pretreatment
Oxycodone 20mg, p.o.: Oxycodone 20mg, p.o.
Oxycodone 0mg, IN: Oxycodone 0mg, IN</description>
          </group>
          <group group_id="O5">
            <title>Placebo Aprepitant/ Oxycodone 0 IN 40 PO</title>
            <description>Placebo aprepitant/ oxycodone 0 IN 40 PO
Aprepitant 0mg: Aprepitant 0mg, p.o. pretreatment
Oxycodone 40mg, p.o.: Oxycodone 40mg, p.o.
Oxycodone 0mg, IN: Oxycodone 0mg, IN</description>
          </group>
          <group group_id="O6">
            <title>Aprepitant 40 mg/ Oxycodone 0 IN 0 PO</title>
            <description>Aprepitant 40 mg/ oxycodone 0 IN 0 PO
Aprepitant 40mg: Aprepitant 40mg, p.o. pretreatment
Oxycodone 0mg, p.o.: Oxycodone 0mg, p.o.
Oxycodone 0mg, IN: Oxycodone 0mg, IN</description>
          </group>
          <group group_id="O7">
            <title>Aprepitant 40 mg/ Oxycodone 0 IN 20 PO</title>
            <description>Aprepitant 40 mg/ oxycodone 0 IN 20 PO
Aprepitant 40mg: Aprepitant 40mg, p.o. pretreatment
Oxycodone 20mg, p.o.: Oxycodone 20mg, p.o.
Oxycodone 0mg, IN: Oxycodone 0mg, IN</description>
          </group>
          <group group_id="O8">
            <title>Aprepitant 40 mg/ Oxycodone 0 IN 40 PO</title>
            <description>Aprepitant 40 mg/ oxycodone 0 IN 40 PO
Aprepitant 40mg: Aprepitant 40mg, p.o. pretreatment
Oxycodone 40mg, p.o.: Oxycodone 40mg, p.o.
Oxycodone 0mg, IN: Oxycodone 0mg, IN</description>
          </group>
          <group group_id="O9">
            <title>Aprepitant 40 mg/ Oxycodone 15 IN 0 PO</title>
            <description>Aprepitant 40 mg/ oxycodone 15 IN 0 PO
Aprepitant 40mg: Aprepitant 40mg, p.o. pretreatment
Oxycodone 0mg, p.o.: Oxycodone 0mg, p.o.
Oxycodone 15mg, IN: Oxycodone 15mg, IN</description>
          </group>
          <group group_id="O10">
            <title>Aprepitant 40 mg/ Oxycodone 30 IN 0 PO</title>
            <description>Aprepitant 40 mg/ oxycodone 30 IN 0 PO
Aprepitant 40mg: Aprepitant 40mg, p.o. pretreatment
Oxycodone 0mg, p.o.: Oxycodone 0mg, p.o.
Oxycodone 30mg, IN: Oxycodone 30mg, IN</description>
          </group>
          <group group_id="O11">
            <title>Aprepitant 200 mg/ Oxycodone 0 IN 0 PO</title>
            <description>Aprepitant 200 mg/ oxycodone 0 IN 0 PO
Aprepitant 200mg: Aprepitant 200mg, p.o. pretreatment
Oxycodone 0mg, p.o.: Oxycodone 0mg, p.o.
Oxycodone 0mg, IN: Oxycodone 0mg, IN</description>
          </group>
          <group group_id="O12">
            <title>Aprepitant 200 mg/ Oxycodone 0 IN 20 PO</title>
            <description>Aprepitant 200 mg/ oxycodone 0 IN 20 PO
Aprepitant 200mg: Aprepitant 200mg, p.o. pretreatment
Oxycodone 20mg, p.o.: Oxycodone 20mg, p.o.
Oxycodone 0mg, IN: Oxycodone 0mg, IN</description>
          </group>
          <group group_id="O13">
            <title>Aprepitant 200 mg/ Oxycodone 0 IN 40 PO</title>
            <description>Aprepitant 200 mg/ oxycodone 0 IN 40 PO
Aprepitant 200mg: Aprepitant 200mg, p.o. pretreatment
Oxycodone 40mg, p.o.: Oxycodone 40mg, p.o.
Oxycodone 0mg, IN: Oxycodone 0mg, IN</description>
          </group>
          <group group_id="O14">
            <title>Aprepitant 200 mg/ Oxycodone 15 IN 0 PO</title>
            <description>Aprepitant 200 mg/ oxycodone 15 IN 0 PO
Aprepitant 200mg: Aprepitant 200mg, p.o. pretreatment
Oxycodone 0mg, p.o.: Oxycodone 0mg, p.o.
Oxycodone 15mg, IN: Oxycodone 15mg, IN</description>
          </group>
          <group group_id="O15">
            <title>Aprepitant 200 mg/ Oxycodone 30 IN 0 PO</title>
            <description>Aprepitant 200 mg/ oxycodone 30 IN 0 PO
Aprepitant 200mg: Aprepitant 200mg, p.o. pretreatment
Oxycodone 0mg, p.o.: Oxycodone 0mg, p.o.
Oxycodone 30mg, IN: Oxycodone 30mg, IN</description>
          </group>
        </group_list>
        <measure>
          <title>Respiration Depression</title>
          <description>Respiration rate measured over 60 seconds. Data were collected across multiple time points, but the peak minimum score was used for this outcome measure.</description>
          <population>Prior laboratory-based within subject studies of the pharmacodynamic response to opioid challenges.</population>
          <units>number of breaths per minute</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="8"/>
                <count group_id="O3" value="8"/>
                <count group_id="O4" value="8"/>
                <count group_id="O5" value="8"/>
                <count group_id="O6" value="8"/>
                <count group_id="O7" value="8"/>
                <count group_id="O8" value="8"/>
                <count group_id="O9" value="8"/>
                <count group_id="O10" value="8"/>
                <count group_id="O11" value="8"/>
                <count group_id="O12" value="8"/>
                <count group_id="O13" value="8"/>
                <count group_id="O14" value="8"/>
                <count group_id="O15" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.75" spread="3.15"/>
                    <measurement group_id="O2" value="11.63" spread="1.60"/>
                    <measurement group_id="O3" value="11.25" spread="1.75"/>
                    <measurement group_id="O4" value="12.13" spread="2.30"/>
                    <measurement group_id="O5" value="10.25" spread="1.98"/>
                    <measurement group_id="O6" value="12.25" spread="2.19"/>
                    <measurement group_id="O7" value="12.25" spread="2.12"/>
                    <measurement group_id="O8" value="11.00" spread="2.33"/>
                    <measurement group_id="O9" value="12.38" spread="1.92"/>
                    <measurement group_id="O10" value="11.63" spread="2.56"/>
                    <measurement group_id="O11" value="14.00" spread="2.33"/>
                    <measurement group_id="O12" value="14.00" spread="2.33"/>
                    <measurement group_id="O13" value="12.13" spread="2.17"/>
                    <measurement group_id="O14" value="12.00" spread="1.93"/>
                    <measurement group_id="O15" value="11.38" spread="3.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Within-subject Crossover Design</title>
          <description>All subjects received exposure to every study condition in random order. This was not a parallel group design.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>No significant adverse effects occurred. No adverse events led to study drop-out.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Sharon Walsh</name_or_title>
      <organization>University of Kentucky</organization>
      <phone>859-257-6485</phone>
      <email>sharon.walsh@uky.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

